Evidence map›Paper›PMID 32596991›Full record

ArticleJournal of cellular and molecular medicine2020

Novel evidence for oncogenic piRNA-823 as a promising prognostic biomarker and a potential therapeutic target in colorectal cancer.

Junlan Feng, Muqing Yang, Qing Wei, Feifei Song, Youhua Zhang, Xiaodong Wang, Bin Liu, Jiyu Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Junlan FengDepartment of General Surgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Muqing YangDepartment of General Surgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Qing WeiDepartment of Pathology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Feifei SongDepartment of Pathology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Youhua ZhangDepartment of Pathology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Xiaodong WangDepartment of General Surgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Bin LiuDepartment of General Surgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.
Jiyu LiDepartment of General Surgery, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China.ORCID 0000-0001-9575-3264
Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

piRNA-823 as a member of the piRNA family is reported to promote tumour cell proliferation in multiple myeloma and hepatocellular cancer. However, few studies on the function of piRNA-823 in colorectal cancer (CRC). Our present study data showed that piRNA-823 plays an oncogene role in CRC cells. Inhibition of piRNA-823 can significantly inhibit the proliferation, invasion and apoptosis resistance of CRC cells. Mechanism studies have shown that piRNA-823 inhibits the ubiquitination of hypoxia-inducible factor-1 alpha (HIF-1α) by up-regulating the expression of Glucose-6-phosphate dehydrogenase (G6PD) and ultimately up-regulates the glucose consumption of carcinoma cells and inhibits the content of intracellular reactive oxygen species (ROS). Therefore, we speculate piRNA-823 promotes the proliferation, invasion and apoptosis resistance of CRC cells by regulating G6PD/HIF-1α pathway. In this study, we set up the cancer-promoting function recovery experiment of piRNA-823 by silencing G6PD gene to confirm the dominance of the above-mentioned pathways. Using clinical samples, we found that overexpression of piRNA-823 correlated with poor overall survival and predicted a poor response to adjuvant chemotherapy of patients with CRC. In a word, our research has further enriched the theory of piRNA-823 promoting the progression of CRC, and laid a solid foundation for the development of piRNA-823-based gene therapy for CRC and its use as a promising prognostic biomarker in CRC patients.

Indexed as

ApoptosisBiomarkers, TumorCell LineCell Line, TumorCell ProliferationColorectal NeoplasmsGene Expression Regulation, NeoplasticHCT116 CellsHEK293 CellsHumansHypoxia-Inducible Factor 1, alpha SubunitOncogenesPrognosisReactive Oxygen SpeciesRNA, Small InterferingSignal TransductionBiomarkers, TumorHypoxia-Inducible Factor 1, alpha SubunitReactive Oxygen SpeciesRNA, Small Interferingcolorectal cancerG6PDglucose consumptionHIF-1αpiRNA-823

Identifiers

PMID32596991
PMCPMC7417729
OpenAlexW3038015929

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.